Diabetic Foot Ulcer
(Heberprot - B)
In Cuba, Heberprot-P is applied for patients with a poor course of the disease, chronic non-healing wounds and patients who do not respond to traditional treatment methods.
Heberprot-P is a drug developed in Cuba by the Center of Genetic Engineering and Biotechnology of Cuba for the treatment of severe diabetic foot ulcers. Its main component is the epidermal growth factor (EGF), and it is administered parenterally (intralesional injection directly into the wound). Approximately 160,000 diabetic foot ulcer patients have been treated with Heberprot-P and achieved success in eliminating the amputation risk was seen in 75% of them.
Growth factor, especially epidermal growth factor receptor (EGF) density, decreased in diabetes patients. In diabetic foot patients, EGF is an important growth factor that regulates cell growth and cell quantity growth by binding to epidermal growth factor receptors (EGFR). When the amount of EGF is reduced, the healing of wounds caused by diabetic foot ulcers is greatly reduced, and eventually the amputation process may be necessary. When Heberprot-P is administered in Cuba, the recovery time increases continuously and steadily.
In Cuba, Heberprot-P is administered for patients with a poor course of diabetic foot ulcer disease, chronic non-healing wounds, and patients who do not respond to traditional methods of treatment.
Each treatment program is regulated by the Cuban Ministry of Health, depending on the severity of the condition and the overall health of the patient.